Thermo Fisher Scientific TMO
SEC filings (XBRL) · quarterly · fiscal year ends December 31
Pick a second metric to compare.
Source: SEC EDGAR 10-Q/10-K XBRL, CIK 97745; every value is traced to its filing on EDGAR. Retrieved Oct 11, 2026. Quarters labelled by fiscal quarter with the calendar period end. Q4 = annual minus Q1–Q3; cash-flow quarters derived from year-to-date figures.
Last 84 quarters
| Q3 2024Sep 28, 2024 | Q4 2024Dec 31, 2024 | Q1 2025Mar 29, 2025 | Q2 2025Jun 28, 2025 | Q3 2025Sep 27, 2025 | Q4 2025Dec 31, 2025 | Q1 2026Mar 28, 2026 | Q2 2026Jun 27, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.6B | $11.4B | $10.4B | $10.9B | $11.1B | $12.2B | $11.0B | $12.0B |
| Operating income | $1.8B | $2.0B | $1.7B | $1.8B | $1.9B | $2.3B | $1.9B | $2.1B |
| Net income | $1.6B | $1.8B | $1.5B | $1.6B | $1.6B | $2.0B | $1.7B | $1.7B |
| Capital spending | $0.3B | $0.5B | $0.4B | $0.3B | $0.4B | $0.5B | $0.4B | $0.5B |
| Operating cash flow | $2.2B | $3.3B | $0.7B | $1.4B | $2.2B | $3.5B | $1.2B | $2.1B |
| Free cash flow | $1.9B | $2.8B | $0.4B | $1.1B | $1.8B | $3.0B | $0.8B | $1.7B |
| Capex / operating cash flow | 12.6% | 14.6% | 50.1% | 21.0% | 18.0% | 13.4% | 31.5% | 21.2% |
| Shares outstanding | 382.5M | 377.3M | 377.5M | 377.6M | 375.7M | 371.5M | 371.6M | 369.7M |
| Share count change, y/y | −1.0% | −1.1% | −1.1% | −1.1% | −1.8% | −1.5% | −1.6% | −2.1% |
| Diluted shares (weighted avg.) | 384.0M | — No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 379.0M | 378.0M | 378.0M | — No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 373.0M | 371.0M |
— Diluted shares (weighted avg.): No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
— Diluted shares (weighted avg.): No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
Diluted shares (weighted avg.): fiscal Q4 is blank because the 10-K gives 12-month figures only.
XBRL tags used
| Revenue | Revenues | Jun 2009 to Dec 2016 |
|---|---|---|
RevenueFromContractWithCustomerExcludingAssessedTax | Apr 2017 to Jun 2026 | |
| Operating income | OperatingIncomeLoss | Jun 2009 to Jun 2026 |
| Net income | NetIncomeLoss | Jun 2009 to Mar 2014 |
NetIncomeLossAvailableToCommonStockholdersBasic | Jun 2014 to Mar 2024 | |
NetIncomeLoss | Jun 2024 to Jun 2026 | |
| Capital spending | PaymentsToAcquirePropertyPlantAndEquipment | Jun 2009 to Jun 2026 |
| Operating cash flow | NetCashProvidedByUsedInOperatingActivities | Jun 2009 to Jun 2026 |
| Free cash flow | ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment | Jun 2009 to Jun 2026 |
| Capex / operating cash flow | capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivities | Jun 2009 to Jun 2026 |
| Shares outstanding | dei:EntityCommonStockSharesOutstanding | Jun 2009 to Jun 2026 |
| Diluted shares (weighted avg.) | WeightedAverageNumberOfDilutedSharesOutstanding | Jun 2009 to Jun 2026 |
Where a company changed tags, each quarter uses the tag it was reported under; the newest tag is primary.